Syntermed has a seasoned executive team that has the right balance of experience in the medical and software field.

Syntermed's Executive Team

Michael Lee

Chairman and CEO

As chairman and chief executive officer for Syntermed, Lee is part of the executive team which oversees Syntermed’s product and business strategy as well as the company's daily operations including business development, finances, sales, marketing, professional services and administration. Lee is also a member of Syntermed’s Board of Directors. With over 30 years of technology and leadership experience, Lee has a strong track record in building teams for marketing, sales, business development, software engineering and has managed all phases of the software business.  Lee served as Vice President for Sales and Business Development, eMarketing for Mobular Technologies where he was part of a team which secured a round of Series A funding. Prior to joining Mobular, Lee was National Sales Director for Commercial Software Products for MessageMedia, Inc. (SoftBank portfolio company and recently acquired by DoubleClick), where he managed a team which grew revenue 300% in just one year. Lee joined Messagemedia when it acquired Revnet Systems, Inc, an early leader in the Internet direct e-mail marketing software segment. Earlier, Lee spent several years at Georgia Tech. First as Director of Sales and Marketing for the Computer-Aided Structural Engineering Center at the Georgia Institute of Technology where he also spent several years developing large scale engineering software solutions, and then later as Manager of Intellectual Property Marketing for the Georgia Tech Research Corporation where he worked with the Advanced Technology Development Center and other Atlanta entrepreneurs to transfer technology from Georgia Tech to the commercial sector. Lee earned both a Masters and Bachelors degree in Structural Engineering with Highest Honor from Georgia Tech and is a member of the Technology Association of Georgia (TAG), the Atlanta CEO forum, a past director of the Atlanta chapter of the American Lung Association, and was a charter member of the Atlanta Peachtree Rotary Club.



Ken Van Train


Since its inception, Ken Van Train has been the President of Syntermed spearheading the software validation and commercialization of Emory Toolbox™ and NeuroQ™ and related medical imaging software applications. A primary responsibility includes the oversight for quality control, customer service and training. Most recently, Van Train was principal Investigator for two NIH Small Business grants (STTR and SBIR) through Syntermed totaling over $3.3 million in funding. His FDA medical device regulatory experience is extensive. Collectively Van Train has guided 22 pre-market notification 510k submissions for Syntermed and other nuclear medicine device companies, all of which have been accepted by the FDA. For more than two decades he served as director of computer research and development at the department of medical physics and imaging, Cedars-Sinai Medical Center. He also served as the president of NucCardiac Software, Inc., a medical device software company for 15 years. While at Cedars-Sinai Medical Center, Van Train was a co-investigator involved with the development, validation, and commercialization of four medical software products: Cedars Planar Quantitative Tl-201, Cedars Quantitative SPECT TL-201, Cedars-Emory CEqual®, and the Emory Cardiac Toolbox. He has authored or co-authored 77 manuscripts and book chapters and 152 abstracts in the field of nuclear medicine and image processing. Ken Van Train received his Masters in Computer Science from Azusa Pacific University in 1996 and holds a Bachelor of Science degree in Biology from Loyola Marymount University, class of 1972.

Ernest V. Garcia, PhD

Chief Scientific Advisor

With a B.S. 1971, M.S., 1972, Ph.D. 1974, University of Miami, Dr. Garcia joined Emory University in 1985 after 12 years of experience in medical imaging obtained at the University of Miami, Florida and at Cedars-Sinai Medical Center/UCLA in Los Angeles. He is currently Professor of Radiology at Emory and a full time researcher. From 1997-2005 He was Vice-chairman of Research for the Department of Radiology at Emory University. From 1993-2000, he was Director of the Emory Center for PET, and the Advanced Imaging Research Center. From 1990-1993, he was the Co-Director of the Emory/Georgia Tech Biomedical Technology Research Center. Dr. Garcia's research interest lies in the areas of medical imaging and bioinformatics. His main area of development has been in the field of quantitative analysis of cardiac images. His techniques have resulted in six commercial products used worldwide for quantifying myocardial perfusion images. He also developed the first computer interface for the real time acquisition and display of 2D-echo images. Dr. Garcia has authored or co-authored over 213 articles, 49 chapters and 7 books in the fields of nuclear medicine, cardiovascular imaging and image processing. He is a member of the editorial boards of the Journal of Nuclear Medicine, the Journal of Nuclear Cardiology, the International Journal of Cardiovascular Imaging, the European Journal of Nuclear Medicine and Molecular Imaging, the Journal of Nuclear Medicine Communications, and Revista Espanola de Medicina Nuclear. He is a past board member of the Society of Nuclear Medicine, the American Society of Nuclear Cardiology, and the Institute for Clinical PET. Dr. Garcia is a past President of the Cardiovascular Council of the Society of Nuclear Medicine, the 1996/97 President of the Institute for Clinical PET (now part of the Academy for Molecular Imaging), the 2002-03 President of the American Society for Nuclear Cardiology and the 2003-04 Founding President of the American Society for Nuclear Cardiology Foundation. In 2006 he was selected by the readers of Medical Imaging Magazine as a Medical Imaging Industry Top 10 Nuclear Medicine Researcher of 2005. At the National Institutes of Health, Dr. Garcia was a member of the Diagnostic Radiology Study Section from 1986-1990. At the Food and Drug Administration, he served on the Radiopharmaceutical Drugs Advisory Committee from 1990-1994.